TEVA PHARMACEUTICAL INDUSTRIES LTD SEC Filing

Bridger Management, LLC filed a Rule 144 notice to sell 150,000 American Depositary Shares of Teva Pharmaceutical Industries, using Piper Sandler & Co. as broker on the NYSE, with an aggregate market value of $4,527,000.

Accepted by SEC EDGAR 12/12/2025 - 04:17 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Bridger Management, LLC filed a Rule 144 notice to sell 150,000 American Depositary Shares of Teva Pharmaceutical Industries, using Piper Sandler & Co. as broker on the NYSE, with an aggregate market value of $4,527,000. The filing states that 1,147,282,512 shares are outstanding.

These 150,000 ADS were acquired on 05/09/2018. Over the past three months, the same seller reported two additional Teva ADS transactions: 200,000 shares sold on 11/06/2025 for gross proceeds of $4,821,880, and 50,000 shares sold on 11/26/2025 for $1,301,505.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Teva (TEVA)'s latest Form 144 filing disclose?

The filing discloses that Bridger Management, LLC has notified its intent to sell 150,000 Teva American Depositary Shares under Rule 144, with an aggregate market value of $4,527,000.

How many Teva (TEVA) shares are planned to be sold in this Form 144?

The notice covers the planned sale of 150,000 American Depositary Shares of Teva, to be executed through Piper Sandler & Co. on the NYSE.

What recent Teva (TEVA) share sales has Bridger Management reported?

Over the past three months, Bridger Management reported selling 200,000 Teva ADS on 11/06/2025 for $4,821,880 and 50,000 ADS on 11/26/2025 for $1,301,505.

When did Bridger Management acquire the Teva (TEVA) shares covered by this Form 144?

The 150,000 Teva American Depositary Shares covered by this notice were acquired on 05/09/2018.

How many Teva (TEVA) shares are outstanding according to the Form 144?

The filing states that there are 1,147,282,512 shares of Teva outstanding.

Which broker will handle the Rule 144 sale of Teva (TEVA) shares?

The planned sale is to be executed through Piper Sandler & Co., located at 1 Greenwich Plaza, Greenwich, CT 06830, with the shares listed on the NYSE.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001166309
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	TEVA PHARMACEUTICAL INDUSTRIES LTD
SEC File Number	001-16174
Address of Issuer	124 Dvora HaNevi'a St Tel Aviv ISRAEL 6944020
Phone	973-914-8213
Name of Person for Whose Account the Securities are To Be Sold	Bridger Management, LLC (1)
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Shareholder

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
American Depositary Shares	Piper Sandler & Co. 1 Greenwich Plaza Greenwich CT 06830	150000	4527000.00	1147282512	12/12/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
American Depositary Shares	05/09/2018	See Remark 2	See Remark 2			150000	05/09/2018	See Remark 2

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Bridger Management, LLC (1) 90 Park Avenue, 40th Floor New York NY 10016	American Depositary Shares	11/06/2025	200000	4821880.00
Bridger Management, LLC (1) 90 Park Avenue, 40th Floor New York NY 10016	American Depositary Shares	11/26/2025	50000	1301505.00

144: Remarks and Signature

Remarks	(1) Bridger Management, LLC ("Bridger") serves as the investment manager of Swiftcurrent Master Fund, Ltd., which holds the American Depositary Shares ("ADSs") representing Ordinary Shares covered by this Form 144. Roberto Mignone, Founder and Managing Partner of Bridger, is a member of the board of directors of the Issuer. (2) The ADSs reported herein to be sold were originally acquired through open market purchases on dates ranging from May 9, 2018 to May 10, 2018.
Date of Notice	12/12/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Bridger Management, LLC, By: /s/ Matthew P. Truax, Chief Operating Officer, General Counsel and Chief Compliance Officer
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)